Cosmos Health Posts Record Q2 Revenue of $19M, Up 29%, and Cuts Liabilities 13%
COSM is trading near its 52-week low of $0.162 (15% above the low) on light trading volume (0.3× avg).
Summary
Cosmos Health reported record Q2 revenue of $18.99M, up 28.8% year-over-year, and H1 revenue of $36.91M, up 29.7%. Adjusted gross profit jumped 58.4% in Q2, with adjusted gross margin expanding 165 basis points to 9.54%. Total liabilities fell 13.3% to $40.79M, and stockholders' equity rose 12.2% to $20.67M. The company also repurchased 5.1M shares for $1.11M under its $5M buyback program. Despite the top-line growth, net loss widened to $6.09M from $2.83M a year ago, driven by $2.65M in non-cash fair-value charges on financing arrangements. The balance sheet improvement and operating leverage are notable, but the company still carries a going concern warning and material internal control weaknesses from its last 10-Q. The market cap is only $12.8M, so the $5M buyback represents a significant capital return. Traders will focus on whether the revenue momentum can translate into sustained profitability and whether the company can address its going concern risk.
At the time of this announcement, COSM was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.